GNOM ETF — Holdings & Analysis

The Global X Genomics & Biotechnology ETF (GNOM) offers targeted exposure to the genomics and biotechnology sectors, with an AUM of $0.05 billion.

GNOM seeks to replicate the Solactive Genomics Index, providing investors access to companies involved in gene editing, DNA sequencing, and other genomic advancements. The ETF's expense ratio is 0.50%, and it distinguishes itself through a concentrated portfolio of 49 holdings focused on innovative healthcare and technology companies. Past performance does not guarantee future results.

Global X - Genomics & Biotechnology ETF (GNOM) ETF — Price, Holdings & Analysis

The Global X Genomics & Biotechnology ETF (GNOM) offers targeted exposure to the genomics and biotechnology sectors, with an AUM of $0.05 billion. GNOM seeks to replicate the Solactive Genomics Index, providing investors access to companies involved in gene editing, DNA sequencing, and other genomic advancements. The ETF's expense ratio is 0.50%, and it distinguishes itself through a concentrated portfolio of 49 holdings focused on innovative healthcare and technology companies. Past performance does not guarantee future results.

ETF Overview

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

GNOM aims to track the Solactive Genomics Index, focusing on companies that are expected to benefit from advancements in genomics and biotechnology. This includes firms involved in gene editing, DNA sequencing, and personalized medicine. The fund's strategy involves a concentrated portfolio of 49 holdings, allowing for targeted exposure to key players in the genomics revolution. GNOM's top holdings include Moderna Inc (7.86%), Praxis Precision Medicines Inc Ordinary Shares (6.23%), and Arrowhead Pharmaceuticals Inc (5.69%), reflecting a focus on companies at the forefront of genomic research and development. With a significant allocation to the healthcare sector (99.7%), GNOM provides investors with a specialized tool for participating in the growth of genomics and biotechnology. The remaining 0.3% is allocated to the technology sector. Past performance does not guarantee future results.

Risk Metrics

GNOM's concentrated portfolio of 49 holdings introduces concentration risk, as the performance of a few key companies can significantly impact the ETF's overall returns. The fund's heavy allocation to the healthcare sector (99.7%) exposes it to sector-specific risks, such as regulatory changes, clinical trial failures, and competition from other biotechnology companies. With a beta of 1.95, GNOM exhibits high volatility compared to the broader market, indicating that it may experience larger price swings. The expense ratio of 0.50% creates an expense drag on returns, which should be considered in the context of the fund's potential performance. Investors should carefully evaluate their risk tolerance and investment objectives before investing in GNOM. Past performance does not guarantee future results.

Expense Ratio

0.50%

What does GNOM hold?

Holding	Weight
Moderna Inc (MRNA)	7.86%
Praxis Precision Medicines Inc Ordinary Shares (PRAX)	6.23%
Arrowhead Pharmaceuticals Inc (ARWR)	5.69%
Illumina Inc (ILMN)	5.13%
Guardant Health Inc (GH)	4.71%
Vertex Pharmaceuticals Inc (VRTX)	4.32%
BioMarin Pharmaceutical Inc (BMRN)	4.31%
Natera Inc (NTRA)	3.91%
BioNTech SE ADR (BNTX)	3.87%
Avidity Biosciences Inc Ordinary Shares (RNAM)	3.75%

How Is the Fund Allocated?

Sector	Weight
Healthcare	99.7%
Technology	0.3%

Country	Weight
United States	83.3%
Netherlands	4.3%
Germany	3.6%
Switzerland	3.2%
United Kingdom	2.4%
Singapore	1.6%
China	1.6%
Other	0.0%

Dividend Yield

1.30%

Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
iShares Russell 2000 ETF (IWM) — 0.19% expense ratio
State Street Financial Select Sector SPDR ETF (XLF) — 0.08% expense ratio
iShares MSCI Emerging Markets ETF (EEM) — 0.72% expense ratio
State Street SPDR S&P 500 ETF (SPY) — 0.09% expense ratio

Global X - MSCI Colombia ETF (GXG) (Equity) — 0.62% expense ratio
Global X China Innovation ETF (KEJI) (Equity) — 0.75% expense ratio
Global X Funds - Global X Nasdaq 100 ESG Covered Call ETF (QYLE) (Equity) — 0.61% expense ratio
Global X - S&P 500 Quality Dividend Covered Call ETF (QDCC) (Equity) — 0.35% expense ratio
Global X - MSCI SuperDividend EAFE ETF (EFAS) (Equity) — 0.55% expense ratio
Global X - Adaptive U.S. Risk Management ETF (ONOF) (Equity) — 0.39% expense ratio

Risk Metrics

Beta: 1.95

Questions & Answers

What is GNOM and what does it track?

The Global X Genomics & Biotechnology ETF (GNOM) is an exchange-traded fund that seeks to replicate the price and yield performance of the Solactive Genomics Index.

This index is designed to track the performance of companies that are involved in the genomics and biotechnology industries.

What is the expense ratio for GNOM?

The expense ratio for the Global X Genomics & Biotechnology ETF (GNOM) is 0.50%. This means that for every $1000 invested in the fund, $5.00 is used to cover the fund's operating expenses.

While this is higher than some broad market ETFs, it is important to consider the specialized nature of the fund's investment strategy.

What are the top holdings in GNOM?

As of 2026-03-15, the top holdings in the Global X Genomics & Biotechnology ETF (GNOM) are concentrated in leading companies within the genomics and biotechnology industries.

The top three holdings are Moderna Inc (MRNA) at 7.86%, Praxis Precision Medicines Inc Ordinary Shares (PRAX) at 6.23%, and Arrowhead Pharmaceuticals Inc (ARWR) at 5.69%.

Is GNOM a good long-term investment?

Whether GNOM is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon.

GNOM provides targeted exposure to the genomics and biotechnology sectors, which have the potential for long-term growth due to advancements in personalized medicine and gene editing. However, the fund's concentrated portfolio and sector-specific focus introduce risks that investors should carefully consider.

How does GNOM compare to similar ETFs?

GNOM differentiates itself through its specific focus on genomics and biotechnology companies. While other healthcare or biotechnology ETFs may offer broader exposure, GNOM provides a more targeted approach to investing in the genomics revolution.

GNOM has an expense ratio of 0.50% and an AUM of $0.05 billion.

Does GNOM pay dividends?

Yes, GNOM does pay dividends. As of 2026-03-15, the dividend yield for the Global X Genomics & Biotechnology ETF (GNOM) is 1.30%.

It's important to note that dividend yields can fluctuate based on market conditions and the performance of the underlying holdings.